A61K - Cooperative Patent Classification

CPC - A61K - 2013.07 - page 14
A61K 9/14 . Particulate form, e.g. powders, { Processes for size reducing of pure drugs or the
resulting products, Pure drug nanoparticles ( microspheres A61K 9/16 ; microcapsules
A61K 9/50 ; nanocapsules, nanoparticles of the matrix type A61K 9/51 ) }
A61K 9/141 . . { Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures,
adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded,
co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates,
co-melts; Drug nanoparticles with adsorbed surface modifiers ( ( co ) spray-dried
products A61K 9/16 , ( co ) lyophilised products A61K 9/19 ; the carrier being
chemically bound to the active ingredient A61K 47/48 ) }
A61K 9/143 . . . { with inorganic compounds }
A61K 9/145 . . . { with organic compounds }
A61K 9/146 . . . { with organic macromolecular compounds }
A61K 9/148 . . . { with compounds of unknown constitution, e.g. material from plants or animals (
with oils, fats, waxes, shellac A61K 9/145 ) }
A61K 9/16 . . Agglomerates ; Granulates ; Microbeadlets; { Microspheres; Pellets; Solid products
obtained by spray drying, spray freeze drying, spray congealing, ( multiple )
emulsion solvent evaporation or extraction ( A61K 9/20 takes precedence if the
final form is a tablet; microspheres with drug-free outer coating, microcapsules
A61K 9/50 ; mixture of different granules, microcapsules, ( coated ) microparticles
A61K 9/50 M; nanoparticles A61K 9/51 ) }
A61K 9/1605 . . . { Excipients; Inactive ingredients }
A61K 9/1611 . . . . { Inorganic compounds }
A61K 9/1617 . . . . { Organic compounds, e.g. phospholipids, fats }
A61K 9/1623 . . . . . { Sugars or sugar alcohols, e.g. lactose; Derivatives thereof;
Homeopathic globules }
A61K 9/1629 . . . . { Organic macromolecular compounds }
A61K 9/1635 . . . . . { obtained by reactions only involving carbon-to-carbon unsaturated
bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates }
A61K 9/1641 . . . . . { obtained otherwise than by reactions only involving carbon-to-carbon
unsaturated bonds, e.g. polyethylene glycol, poloxamers }
A61K 9/1647 . . . . . . { Polyesters, e.g. poly(lactide-co-glycolide) }
A61K 9/1652 . . . . . { Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (
homeopathic globules A61K 9/1623 ) }
A61K 9/1658 . . . . . { Proteins, e.g. albumin, gelatin }
A61K 9/1664 . . . . { Compounds of unknown constitution, e.g. material from plants or animals (
oils, fats, waxes, shellac A61K 9/1617 ) }
A61K 9/167 . . . { with an outer layer or coating comprising drug; with chemically bound drugs or
non-active substances on their surface ( with further drug-free outer coating
A61K 9/50 K ) }
A61K 9/1676 . . . . { having a drug-free core with discrete complete coating layer containing
drug ( adsorbates of liquid drug formulations on inert powders without
simultaneous granulation step A61K 9/14 H; with further drug-free outer
coating A61K 9/5078 ; drug conjugated to non-active particles A61K
47/48853 ) }
A61K 9/1682 . . . { Processes }
A61K 9/1688 . . . . { resulting in pure drug agglomerate optionally containing up to 5% of
excipient }
A61K 9/1694 . . . . { resulting in granules or microspheres of the matrix type containing more
than 5% of excipient }